Highest-materiality recent filing
Viskase Holdings adopts Section 382 Rights Plan to protect NOL assets; threshold at 4.9%
Declared dividend of one right per common share; record date May 15, 2026; exercise price $30 per right.
Viskase posts $65.5M net loss in 2025; auditor flags going concern doubt
Net loss attributable to Viskase of $65.5M in 2025 vs loss of $5.4M in 2024; EPS of ($0.49).
Two Viskase board members resign; CEO Davis and Icahn affiliate Pettit appointed
Peter K. Shea and Randolph C. Read resigned from Board on April 29; resignations not due to disagreement.
Viskase extends credit maturity to Aug 2027, raises interest rates 100bps
Maturity of credit facility extended from Aug 13, 2026 to Aug 13, 2027.
Viskase Holdings appoints Grant Thornton as auditor, dismissing EisnerAmper post-merger
EisnerAmper dismissed as independent auditor; no disagreements or reportable events from 2024-2026.
Viskase appoints Michael Blecic as CFO and Joseph King as EVP
Michael Blecic, age 57, appointed CFO effective April 10, 2026; previously VP, CAO, Treasurer at Viskase Companies.
Enzon completes all-stock merger with Viskase; combined company renamed Viskase Holdings
Enzon shareholders own ~45%, Viskase shareholders ~55% of combined company.
Enzon completes exchange offer for Series C Preferred Stock; no terms in filing
Exchange offer for Series C Non-Convertible Redeemable Preferred Stock completed on March 25, 2026.
Enzon announces 1-for-100 reverse stock split effective March 24, 2026; pending merger with Viskase
Reverse stock split effective 4:30 pm ET March 24; OTCQB trading starts March 25 under symbol ENZND for 20 days.
Enzon extends exchange offer for Series C Preferred Stock to March 24, 2026
Enzon issued press release on March 19, 2026 extending the expiration of its exchange offer for Series C Preferred Stock.
Enzon extends shareholder rights plan expiration to March 24, 2026 via Tenth Amendment
Tenth Amendment to Section 382 Rights Agreement extends Final Expiration Date from noon March 18 to noon March 24, 2026.
Enzon extends exchange offer for Series C Preferred to March 19, 2026
Exchange offer for Series C Non-Convertible Redeemable Preferred now expires 5:00 p.m. ET on March 19, 2026.
Enzon extends rights agreement to March 18 and exchange offer to March 16
Ninth Amendment extends Section 382 Rights Agreement expiration to noon, March 18, 2026.
Enzon extends exchange offer for Series C Preferred to March 11, 2026
Exchange offer expiration extended to one minute after 11:59 p.m. ET on March 11, 2026.
Enzon extends Series C Preferred exchange offer to Mar 9; rights plan extended to Mar 11
Exchange offer for Series C Preferred Stock extended to 11:59 p.m. ET on March 9, 2026.
Enzon stockholders approve 1-for-100 reverse stock split and merger with Viskase
Reverse stock split (1:100) approved by 55.2% of outstanding shares; merger proposal approved by 57.1%.
Enzon extends stockholder rights plan expiration to March 2, 2026
Seventh Amendment to Section 382 Rights Agreement executed January 30, 2026.
Enzon Pharmaceuticals extends poison pill expiration to Jan 31, 2026
Sixth Amendment extends Section 382 Rights Agreement Final Expiration Date from Dec 31, 2025 to Jan 31, 2026.
Enzon amends Viskase merger: Viskase holders get 55% of combined co; reverse split 1-for-100
Viskase stockholders will own 55% of combined company post-merger (up from prior ratio); Enzon stockholders 45%.
Enzon extends shareholder rights plan expiration to Dec 31, 2025
Fifth Amendment to Section 382 Rights Agreement extends Final Expiration Date from Sept 30, 2025 to Dec 31, 2025.
Enzon and Viskase sign merger; Enzon shareholders to own ~2% of combined co
Enzon to acquire Viskase in all-stock reverse merger; combined company will be named "Viskase Holdings, Inc." and trade on OTCQX.
Enzon extends shareholder rights plan expiration to June 30, 2026
Third Amendment to Section 382 Rights Agreement extends final expiration date from March 31, 2025 to June 30, 2026.
Enzon appoints Stephen T. Wills to board; forms special committee to evaluate Viskase proposal
Board increased to four; Stephen T. Wills appointed as director effective January 7, 2025.
Enzon declares $31.86/share Series C preferred dividend payable Jan 9, 2025
Aggregate dividend of $1,274,400 declared on 40,000 outstanding shares of Series C Preferred Stock.
Enzon shareholders approve all four proposals at 2024 annual meeting
Quorum of 58,112,406 shares (78% of entitled votes) present at Sept. 26 meeting.
Enzon sets Sept 26, 2024 annual meeting; record date Aug 7. Stockholder proposals due July 12.
Annual meeting scheduled for September 26, 2024.
Enzon sets 2024 annual meeting for Sep 26; proxy deadline Jul 12
Annual Meeting of Stockholders scheduled for September 26, 2024.
Enzon regains OTCQX compliance after stock price recovers above $0.10
Received OTCQX notification on June 10, 2024 that compliance regained.
Enzon extends shareholder rights plan expiration to March 31, 2025
Second Amendment to Section 382 Rights Agreement extends final expiration date from June 2, 2024 to March 31, 2025.
On April 29, 2026, Peter K. Shea notified the Company of his decision to resign as a member of the Board of Directors (the "Board"), including from his service on the Company’s Audit Committee.
On April 30, 2026, the Company appointed each of Mr. Thomas D. Davis, the Company’s Chief Executive Officer, and Mr. Craig Pettit to serve as members of the Board to fill the vacancies created by the resignations of Messrs. Peter Shea and Read.
Also, on April 29, 2026, Randolph C. Read notified the Company of his decision to resign as a member of the Board.
On April 30, 2026, the Company appointed each of Mr. Thomas D. Davis, the Company’s Chief Executive Officer, and Mr. Craig Pettit to serve as members of the Board to fill the vacancies created by the resignations of Messrs. Peter Shea and Read.
On January 7, 2025, the Board of Directors (the “Board”) of Enzon Pharmaceuticals, Inc. (the “Company”) approved an increase in the number of directors on the Board to four and appointed Stephen T. Wills as a director, effective immediately.
Max materiality 0.90 · Median 0.40 · Most common event other_material